Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
JM Gatell
Observed names:
J Gatell,
J M Gatell,
J. M. Gatell,
J.M. Gatell
Institutions:
Hospital Universitario La Paz,
Hospital La Paz Institute for Health Research
Observed institutions:
Hospital Universitario La Paz,
The Royal Free Hospital,
Hospital La Paz Institute for Health Research,
Hospital Clínic de Barcelona,
Vall d'Hebron Hospital Universitari,
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer,
Universitat de Barcelona
show all 7
OpenAlex ID:
A5109955506
Mitochondrial Effects of HIV Infection on the Peripheral Blood Mononuclear Cells of HIV-Infected Patients Who Were Never Treated with Antiretrovirals
2004
·
O. Miro
, S. Lopez
, et al.
·
Clinical Infectious Diseases
·
166
A nosocomial outbreak of influenza during a period without influenza epidemic activity
2003
·
J.P. Horcajada
, T. Pumarola
, et al.
·
European Respiratory Journal
·
128
PDF
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
2017
·
Federico Pulido
, Esteban Ribera
, et al.
·
Clinical Infectious Diseases
·
122
PDF
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
2017
·
Chloe Orkin
, Jean-Michel Molina
, et al.
·
The Lancet HIV
·
104
Efficacy and Safety of Fosfomycin Plus Imipenem as Rescue Therapy for Complicated Bacteremia and Endocarditis Due to Methicillin-Resistant Staphylococcus aureus: A Multicenter Clinical Trial
2014
·
A. del Rio
, O. Gasch
, et al.
·
Clinical Infectious Diseases
·
93
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts*
2008
·
E De Lazzari
, A León
, et al.
·
HIV Medicine
·
71
PDF
Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia
2011
·
M. Medina-Ramírez
, V. Sánchez-Merino
, et al.
·
Journal of Virology
·
56
Comparison of the Prognostic Value of Liver Biopsy and FIB-4 Index in Patients Coinfected With HIV and Hepatitis C Virus
2014
·
Juan Berenguer
, Francisco X. Zamora
, et al.
·
Clinical Infectious Diseases
·
44
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
2017
·
Pedro Cahn
, Richard Kaplan
, et al.
·
The Lancet HIV
·
42
PDF
Pharmacokinetic interaction between rifampicin and ritonavir‐boosted atazanavir in HIV‐infected patients*
2007
·
J Mallolas
, M Sarasa
, et al.
·
HIV Medicine
·
37
Kidney disease in antiretroviral‐naïve HIV ‐positive adults with high CD 4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT S trategic T iming of A nti R etroviral T reatment ( START ) trial
2015
·
AC Achhra
, A Mocroft
, et al.
·
HIV Medicine
·
29
Quality of Life in Patients Treated with First-Line Antiretroviral Therapy Containing Nevirapine And/Or Efavirenz
2004
·
the 2NN study group
, Frank van Leth
, et al.
·
Antiviral Therapy
·
29
PDF
Influenza A H1N1 in HIV-infected adults*
2011
·
E Martínez
, MA Marcos
, et al.
·
HIV Medicine
·
26
Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study
2012
·
P. Monteiro
, I. Perez
, et al.
·
Journal of Antimicrobial Chemotherapy
·
25
Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study
2012
·
M. Masia
, E. Martinez
, et al.
·
Journal of Antimicrobial Chemotherapy
·
20
Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus
2011
·
J. Berenguer
, M. A. von Wichmann
, et al.
·
Journal of Antimicrobial Chemotherapy
·
20
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
2019
·
Erkki Lathouwers
, Eric Y Wong
, et al.
·
AIDS Research and Human Retroviruses
·
17
PDF
Alternation of Antiretroviral Drug Regimens for HIV Infection. Efficacy, Safety and Tolerability at Week 96 of the Swatch Study
2004
·
on behalf of the Swatch Study Team
, Eugenia Negredo
, et al.
·
Antiviral Therapy
·
16
PDF
Effects of highly active antiretroviral therapy on vaccine‐induced humoral immunity in HIV‐infected adults
2010
·
R González
, P Castro
, et al.
·
HIV Medicine
·
11
PDF
Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: Eurosida Study
2004
·
on behalf of the EuroSIDA Study Group
, Cecilia Cabrera
, et al.
·
Antiviral Therapy
·
11
PDF
Efficacy and Safety of atazanavir (ATV) Based HAART in patients switched from a stable boosted/unboosted protease-inhibitor (PI) treatment. The SWAN study
2005
·
JM Gatell
, Dominique Salmon‐Céron
, et al.
·
6
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
1997
·
J M Raboud
, J S Montaner
, et al.
·
PubMed
·
5
Fe de errores: Polifarmacia e interacciones farmacológicas potenciales en una población envejecida con infección por el VIH
2017
·
Carla Bastida
, Amy Baumann Grau
, et al.
·
Farmacia Hospitalaria
·
2
Efficacy of atazanavir (ATV) based HAART in patients switched from a stable PI or boosted PI (PI/r) treatment. Planned week 24 analysis of a phase IIIb 48 week multicenter, open-label, randomized, prospective trial. The SWAN study
2005
·
JM Gatell
, Dominique Salmon‐Céron
, et al.
·
2
Efficacy and safety of switching from lopinavir/r to atazanavir/r in suppressed patients receiving a LPV/r-containing HAART: ATAZIP 96-week results
2008
·
J Mallolas
, D Podzamczer
, et al.
·
Journal of the International AIDS Society
·
1
PDF
Show more works
View as search
Works count:
34
Citation count:
1,081
H-index:
17
I10-index:
20
Year
Topic
Type